300601 康泰生物
已收盘 02-10 15:00:00
资讯
新帖
简况
康泰生物与阿斯利康4亿美元合作告吹，涉疫苗研发生产
新京报 · 02-09 17:53
康泰生物与阿斯利康4亿美元合作告吹，涉疫苗研发生产
28亿元项目黄了！康泰生物终止与阿斯利康合资设立疫苗企业
第一财经 · 02-08 12:13
28亿元项目黄了！康泰生物终止与阿斯利康合资设立疫苗企业
康泰生物最新公告：持股5%以上股东袁莉萍拟在一致行动人之间内部转让不超过2.00%股份
证券之星 · 02-06
康泰生物最新公告：持股5%以上股东袁莉萍拟在一致行动人之间内部转让不超过2.00%股份
康泰生物最新公告：终止设立合资公司
证券之星 · 02-06
康泰生物最新公告：终止设立合资公司
康泰生物最新公告：全资子公司民海生物荣获江苏省科技进步奖二等奖
证券之星 · 02-06
康泰生物最新公告：全资子公司民海生物荣获江苏省科技进步奖二等奖
康泰生物最新公告：副总裁于冰因个人原因辞职
证券之星 · 02-06
康泰生物最新公告：副总裁于冰因个人原因辞职
康泰生物：预计2025年全年归属净利润盈利4900万元至7300万元
证券之星 · 01-29
康泰生物：预计2025年全年归属净利润盈利4900万元至7300万元
康泰生物涨7.51%，中国银河二个月前给出“买入”评级
证券之星 · 01-26
康泰生物涨7.51%，中国银河二个月前给出“买入”评级
康泰生物（300601）股东杜伟民质押560万股，占总股本0.5%
证券之星 · 01-20
康泰生物（300601）股东杜伟民质押560万股，占总股本0.5%
康泰生物（300601）股东杜伟民质押3000万股，占总股本2.69%
证券之星 · 01-16
康泰生物（300601）股东杜伟民质押3000万股，占总股本2.69%
康泰生物最新公告：吸附无细胞百白破（组分）联合疫苗临床试验申请获受理
证券之星 · 01-08
康泰生物最新公告：吸附无细胞百白破（组分）联合疫苗临床试验申请获受理
康泰生物（300601）股东杜伟民质押680万股，占总股本0.61%
证券之星 · 01-07
康泰生物（300601）股东杜伟民质押680万股，占总股本0.61%
康泰生物2025年第四季度“康泰转2”转股42张，总股本微增至约11.17亿股
中金财经 · 01-05
康泰生物2025年第四季度“康泰转2”转股42张，总股本微增至约11.17亿股
股市必读：12月31日康泰生物现1笔大宗交易 机构净卖出733.45万元
证券之星 · 01-05
股市必读：12月31日康泰生物现1笔大宗交易 机构净卖出733.45万元
每周股票复盘：机构净卖出康泰生物（300601）733.45万元
证券之星 · 01-03
每周股票复盘：机构净卖出康泰生物（300601）733.45万元
12月31日康泰生物现1笔大宗交易 机构净卖出733.45万元
证券之星 · 2025-12-31
12月31日康泰生物现1笔大宗交易 机构净卖出733.45万元
康泰生物(300601.SZ)：五联疫苗开启Ⅲ期临床试验
智通财经 · 2025-12-24
康泰生物(300601.SZ)：五联疫苗开启Ⅲ期临床试验
康泰生物：2025年上半年研发投入3.34亿元
证券之星 · 2025-12-18
康泰生物：2025年上半年研发投入3.34亿元
康泰生物（300601）披露重组乙肝疫苗获临床试验批准，12月17日股价上涨1.15%
证券之星 · 2025-12-17
康泰生物（300601）披露重组乙肝疫苗获临床试验批准，12月17日股价上涨1.15%
康泰生物(300601.SZ)：重组乙型肝炎疫苗(酿酒酵母)(60μg)新增适用人群项目取得临床试验批准
智通财经 · 2025-12-17
康泰生物(300601.SZ)：重组乙型肝炎疫苗(酿酒酵母)(60μg)新增适用人群项目取得临床试验批准
加载更多
公司概况
公司名称：
深圳康泰生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2017-02-07
主营业务：
深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是13价肺炎球菌多糖结合疫苗、无细胞百白破b型流感嗜血杆菌联合疫苗（四联苗）、冻干人用狂犬病疫苗（人二倍体细胞）、23价肺炎球菌多糖疫苗、重组乙型肝炎疫苗(酿酒酵母)、b型流感嗜血杆菌结合疫苗、吸附无细胞百白破联合疫苗、水痘减毒活疫苗。
发行价格：
3.29
{"stockData":{"symbol":"300601","market":"SZ","secType":"STK","nameCN":"康泰生物","latestPrice":15.38,"timestamp":1770707010000,"preClose":15.49,"halted":0,"volume":10833508,"delay":0,"changeRate":-0.0071,"floatShares":900000000,"shares":1117000000,"eps":-0.0898,"marketStatus":"已收盘","change":-0.11,"latestTime":"02-10 15:00:00","open":15.53,"high":15.55,"low":15.36,"amount":167000000,"amplitude":0.0123,"askPrice":15.38,"askSize":154,"bidPrice":15.37,"bidSize":281,"shortable":0,"etf":0,"ttmEps":-0.0898,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770773400000},"marketStatusCode":5,"adr":0,"adjPreClose":15.49,"symbolType":"stock","openAndCloseTimeList":[[1770687000000,1770694200000],[1770699600000,1770706800000]],"highLimit":17.04,"lowLimit":13.94,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1116929755,"isCdr":false,"pbRate":1.9,"roa":"--","roe":"0.51%","epsLYR":0.18,"committee":0.587613,"marketValue":17178000000,"turnoverRate":0.012,"status":1,"floatMarketCap":13848000000},"requestUrl":"/m/hq/s/300601","defaultTab":"news","newsList":[{"id":"2610636394","title":"康泰生物与阿斯利康4亿美元合作告吹，涉疫苗研发生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2610636394","media":"新京报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610636394?lang=zh_cn&edition=full","pubTime":"2026-02-09 17:53","pubTimestamp":1770630780,"startTime":"0","endTime":"0","summary":"彼时，双方在协议中约定，公司和阿斯利康计划在经开区共同成立合资公司，开展全球创新疫苗在中国地区的开发注册、本地化生产和商业化。康泰生物2024年营利双降，营收为26.52亿元，同比下降23.75%；实现净利润2.02亿元，同比下滑76.59%。2025年康泰生物则增收不增利。康泰生物表示，因四联苗受百白破免疫程序调整、营业成本上升及研发投入增加等因素影响，致使2025年度净利润较上年同期下降。","market":"us","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl882026291747522902791.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl882026291747522902791.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1770630815168378.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1770630815168378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["LU0320765992.SGD","LU2462157665.USD","LU1829250122.USD","LU0109394709.USD","BK0046","159646","BK4585","BK4007","LU2236285917.USD","BK0239","BK4568","BK0201","BK4588","LU0889565916.HKD","LU2417539215.USD","AZN","300601","LU2456880835.USD"],"gpt_icon":0},{"id":"2609270915","title":"28亿元项目黄了！康泰生物终止与阿斯利康合资设立疫苗企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2609270915","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609270915?lang=zh_cn&edition=full","pubTime":"2026-02-08 12:13","pubTimestamp":1770523980,"startTime":"0","endTime":"0","summary":"康泰生物称“市场环境剧烈变化”。 康泰生物与阿斯利康投资（中国）有限公司设立合资疫苗企业的计划最终还是告吹了。 近日，康泰生物发布公告称，经各方审慎评估与友好协商，决定终止《经济发展合作协议》《条款清单》及对外投资设立合资公司事项。合资公司也将成为阿斯利康在中国首个且唯一的疫苗生产基地。 截至目前，合资公司尚未成立，康泰生物也尚未实际出资。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-02-08/doc-inhmapyc9468285.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-08/doc-inhmapyc9468285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AZN","BK0046","BK4568","LU0109394709.USD","LU1829250122.USD","LU2462157665.USD","LU2236285917.USD","LU2456880835.USD","BK0201","BK4007","LU0889565916.HKD","LU2417539215.USD","300601","LU0320765992.SGD","BK4585","BK4588","159646","BK0239"],"gpt_icon":0},{"id":"2609595896","title":"康泰生物最新公告：持股5%以上股东袁莉萍拟在一致行动人之间内部转让不超过2.00%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2609595896","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609595896?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:51","pubTimestamp":1770382277,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，公司持股5%以上股东袁莉萍拟将其持有的博普私募基金产品的部分公司股份不超过22,330,000股（不超过公司总股本比例2.00%），通过大宗交易方式转让给其一致行动人华宝万盈私募基金产品。此次股份转让计划是股东及其一致行动人之间的内部转让，不涉及向市场减持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600038548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","300601","BK0239"],"gpt_icon":0},{"id":"2609841595","title":"康泰生物最新公告：终止设立合资公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2609841595","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609841595?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:50","pubTimestamp":1770382200,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，此前披露，公司拟与阿斯利康投资（中国）有限公司（以下简称“阿斯利康”）聚焦疫苗建立战略合作伙伴关系，并在北京经济技术开发区（以下简称“经开区”）设立合资公司。由于市场环境剧烈变化，行业面临比较大的下行压力，新增投资疫苗产业风险比较高，经各方审慎评估与友好协商，决定终止《经济发展合作协议》《条款清单》及对外投资设立合资公司事项。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600038549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300601","BK0201","BK0239"],"gpt_icon":0},{"id":"2609593041","title":"康泰生物最新公告：全资子公司民海生物荣获江苏省科技进步奖二等奖","url":"https://stock-news.laohu8.com/highlight/detail?id=2609593041","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609593041?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:39","pubTimestamp":1770381590,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，公司全资子公司北京民海生物科技有限公司作为重要参与单位完成的“新发病毒性传染病快速确认与精准防控关键技术创新及应用”项目荣获江苏省科学技术进步奖二等奖。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600038232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0239","BK0046"],"gpt_icon":0},{"id":"2609567639","title":"康泰生物最新公告：副总裁于冰因个人原因辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2609567639","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609567639?lang=zh_cn&edition=full","pubTime":"2026-02-06 19:20","pubTimestamp":1770376850,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，公司副总裁于冰因个人原因申请辞去公司副总裁职务，其原定任期至2028年1月21日。于冰辞职后，仍在公司担任其他职务。截至公告披露日，于冰未持有公司股份，不存在应当履行而未履行的承诺事项。其辞任不会影响公司正常生产经营和运作。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600035348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0046","BK0239"],"gpt_icon":0},{"id":"2607088556","title":"康泰生物：预计2025年全年归属净利润盈利4900万元至7300万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607088556","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607088556?lang=zh_cn&edition=full","pubTime":"2026-01-29 18:10","pubTimestamp":1769681434,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物发布业绩预告，预计2025年全年归属净利润盈利4900万元至7300万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900031763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601"],"gpt_icon":0},{"id":"2606297130","title":"康泰生物涨7.51%，中国银河二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2606297130","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606297130?lang=zh_cn&edition=full","pubTime":"2026-01-26 15:52","pubTimestamp":1769413961,"startTime":"0","endTime":"0","summary":"今日康泰生物涨7.51%，收盘报17.17元。2025年10月28日，中国银河研究员程培,宋丽莹发布了对康泰生物的研报《2025年三季报点评：海外营收高增长，关注多联多价苗研发进展》，该研报对康泰生物给出“买入”评级。研报中预计公司2025-2027年分别实现归母净利润1.22/4.21/5.10亿元，对应PE分别为151/44/36倍，维持“推荐”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为29.65%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600015291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","601881"],"gpt_icon":0},{"id":"2604619433","title":"康泰生物（300601）股东杜伟民质押560万股，占总股本0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604619433","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604619433?lang=zh_cn&edition=full","pubTime":"2026-01-20 18:30","pubTimestamp":1768905052,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物1月20日公开信息显示，股东杜伟民向招商证券股份有限公司合计质押560.0万股，占总股本0.5%。质押详情见下表：截止本公告日，股东杜伟民已累计质押股份5898.0万股，占其持股总数的20.71%。康泰生物主营业务：人用疫苗的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000032286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0239","BK0046","300601"],"gpt_icon":0},{"id":"2603298962","title":"康泰生物（300601）股东杜伟民质押3000万股，占总股本2.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603298962","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603298962?lang=zh_cn&edition=full","pubTime":"2026-01-16 18:31","pubTimestamp":1768559463,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物1月16日公开信息显示，股东杜伟民向国金证券资产管理有限公司合计质押3000.0万股，占总股本2.69%。质押详情见下表：截止本公告日，股东杜伟民已累计质押股份5338.0万股，占其持股总数的18.74%。康泰生物主营业务：人用疫苗的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600032641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0239","BK0046","BK0201"],"gpt_icon":0},{"id":"2601611365","title":"康泰生物最新公告：吸附无细胞百白破（组分）联合疫苗临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601611365","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601611365?lang=zh_cn&edition=full","pubTime":"2026-01-08 19:19","pubTimestamp":1767871195,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称，公司全资子公司民海生物研发的吸附无细胞百白破（组分）联合疫苗（成人青少年及儿童用）临床试验申请获国家药监局受理。该疫苗适用于成人、青少年及儿童，用于预防百日咳、白喉、破伤风。目前国内暂无同类产品获批上市。此申请获受理标志着公司在多联疫苗及成人疫苗领域取得新进展，有利于丰富产品布局，提升核心竞争力和市场地位。但疫苗研发周期长，临床试验和注册申报等环节存在不确定性，公司将及时履行信息披露义务。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800033470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0239","BK0046"],"gpt_icon":0},{"id":"2601746668","title":"康泰生物（300601）股东杜伟民质押680万股，占总股本0.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601746668","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601746668?lang=zh_cn&edition=full","pubTime":"2026-01-07 18:35","pubTimestamp":1767782140,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物1月7日公开信息显示，股东杜伟民向招商证券股份有限公司合计质押680.0万股，占总股本0.61%。质押详情见下表：截止本公告日，股东杜伟民已累计质押股份5138.0万股，占其持股总数的18.04%。康泰生物主营业务：人用疫苗的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700031230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300601","BK0201"],"gpt_icon":0},{"id":"2601885858","title":"康泰生物2025年第四季度“康泰转2”转股42张，总股本微增至约11.17亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885858","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601885858?lang=zh_cn&edition=full","pubTime":"2026-01-05 19:33","pubTimestamp":1767612795,"startTime":"0","endTime":"0","summary":"中访网数据 深圳康泰生物制品股份有限公司于2026年1月5日发布公告，披露了其可转换公司债券“康泰转2”在2025年第四季度的转股情况。报告期内，共有42张“康泰转2”转换为公司股票，对应转股金额为4,200元，合计转为264股“康泰生物”A股股票。转股完成后，公司总股本由约11.17亿股微增至约11.17亿股。截至2025年12月31日，“康泰转2”剩余数量为19,989,910张，剩余票面总金额约为19.99亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260105/31915962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300601","BK0201","BK0239","BK0046"],"gpt_icon":0},{"id":"2601029089","title":"股市必读：12月31日康泰生物现1笔大宗交易 机构净卖出733.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601029089","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601029089?lang=zh_cn&edition=full","pubTime":"2026-01-05 02:58","pubTimestamp":1767553090,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，康泰生物报收于14.77元，下跌0.61%，换手率0.73%，成交量6.59万手，成交额9754.82万元。当日关注点来自交易信息汇总：12月31日主力资金净流出1207.98万元，占总成交额12.38%。大宗交易12月31日康泰生物现1笔大宗交易，机构净卖出733.45万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500000922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0201","BK0046","300601"],"gpt_icon":0},{"id":"2600067641","title":"每周股票复盘：机构净卖出康泰生物（300601）733.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600067641","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600067641?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:44","pubTimestamp":1767379451,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，康泰生物报收于14.77元，较上周的15.12元下跌2.31%。本周，康泰生物12月29日盘中最高价报15.28元。12月31日盘中最低价报14.74元。康泰生物当前最新总市值164.97亿元，在生物制品板块市值排名17/51，在两市A股市值排名1191/5181。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000661.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","BK0239","300601"],"gpt_icon":0},{"id":"2595720346","title":"12月31日康泰生物现1笔大宗交易 机构净卖出733.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595720346","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595720346?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:33","pubTimestamp":1767173636,"startTime":"0","endTime":"0","summary":"证券之星消息，12月31日康泰生物发生大宗交易，交易数据如下：大宗交易成交价格14.77元，成交49.66万股，成交金额733.45万元，买方营业部为广发证券股份有限公司广州临江大道证券营业部，卖方营业部为机构专用。近三个月该股共发生2笔大宗交易，合计成交9536.0手。截至2025年12月31日收盘，康泰生物报收于14.77元，下跌0.61%，换手率0.73%，成交量6.59万手，成交额9754.82万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100031446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0046","BK0239","BK0201"],"gpt_icon":0},{"id":"2593478445","title":"康泰生物(300601.SZ)：五联疫苗开启Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2593478445","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593478445?lang=zh_cn&edition=full","pubTime":"2025-12-24 16:57","pubTimestamp":1766566638,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物 发布公告，公司全资子公司北京民海生物科技有限公司研发的吸附无细胞百白破灭活脊髓灰质炎和b型流感嗜血杆菌联合疫苗已完成Ⅲ期临床试验准备工作，正式开启Ⅲ期临床试验，并于今日成功完成首例受试者入组。本次五联疫苗开启Ⅲ期临床试验并成功完成首例受试者入组，表明该产品研发取得了阶段性进展，公司将积极推动该产品的临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康泰生物(300601.SZ)：五联疫苗开启Ⅲ期临床试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0046","BK0201","300601","159646"],"gpt_icon":0},{"id":"2592290549","title":"康泰生物：2025年上半年研发投入3.34亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592290549","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592290549?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:48","pubTimestamp":1766062131,"startTime":"0","endTime":"0","summary":"证券之星消息，康泰生物12月17日在投资者关系平台上答复投资者关心的问题。康泰生物回复：您好，公司始终将研发创新作为驱动公司可持续发展的核心战略，长期保持高强度、持续性的研发投入，以技术壁垒构筑企业核心竞争力，2025年上半年公司研发投入为3.34亿元，占当期营业收入的23.96%，相较于2024年上半年同比增加了41.52%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800035253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0239","BK0046"],"gpt_icon":0},{"id":"2592915818","title":"康泰生物（300601）披露重组乙肝疫苗获临床试验批准，12月17日股价上涨1.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592915818","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592915818?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:12","pubTimestamp":1765980744,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，康泰生物报收于15.0元，较前一交易日上涨1.15%，最新总市值为167.54亿元。公司近日发布公告称，其研发的重组乙型肝炎疫苗新增适用人群项目，获得国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意在16-64岁慢性乙肝临床治愈人群中开展预防HBsAg复阳的临床试验。该疫苗拟用于降低慢性乙肝临床治愈后HBsAg复阳风险，目前全球尚无同类产品获批用于该人群。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700039349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0239","BK0046","300601"],"gpt_icon":0},{"id":"2592969169","title":"康泰生物(300601.SZ)：重组乙型肝炎疫苗(酿酒酵母)(60μg)新增适用人群项目取得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592969169","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592969169?lang=zh_cn&edition=full","pubTime":"2025-12-17 18:09","pubTimestamp":1765966180,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)公告，公司研发的重组乙型肝炎疫苗(酿酒酵母)(60μg)新增适用人群项目于今日获得国家药品监督管理局出具的《药物临床试验批准通知书》，本品符合药品注册的有关要求，批准本品在慢性乙型肝炎功能性(临床)治愈人群中开展预防HBsAg复阳的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康泰生物(300601.SZ)：重组乙型肝炎疫苗(酿酒酵母)(60μg)新增适用人群项目取得临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","BK0201","BK0046","BK0239","300601"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770725009404,"stockEarnings":[{"period":"1week","weight":0.0157},{"period":"1month","weight":-0.0288},{"period":"3month","weight":-0.1149},{"period":"6month","weight":-0.1258},{"period":"1year","weight":0.0127},{"period":"ytd","weight":0.0487}],"compareEarnings":[{"period":"1week","weight":0.0267},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0301},{"period":"6month","weight":0.1194},{"period":"1year","weight":0.248},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳康泰生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"63422人(较上一季度增加3.15%)","perCapita":"14196股","listingDate":"2017-02-07","address":"广东省深圳市南山区粤海街道科技园社区科发路222号康泰集团大厦","registeredCapital":"111692万元","survey":" 深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是13价肺炎球菌多糖结合疫苗、无细胞百白破b型流感嗜血杆菌联合疫苗（四联苗）、冻干人用狂犬病疫苗（人二倍体细胞）、23价肺炎球菌多糖疫苗、重组乙型肝炎疫苗(酿酒酵母)、b型流感嗜血杆菌结合疫苗、吸附无细胞百白破联合疫苗、水痘减毒活疫苗。","listedPrice":3.29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康泰生物,300601,康泰生物股票,康泰生物股票老虎,康泰生物股票老虎国际,康泰生物行情,康泰生物股票行情,康泰生物股价,康泰生物股市,康泰生物股票价格,康泰生物股票交易,康泰生物股票购买,康泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}